B+
Bull case
25%
Probability
Target price
$330.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
ALNY
AlnylamCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$255.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$175.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
-0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+61.5
Score
AI commentary
News tone is negative after the earnings-related guidance cut and sharp reported share-price decline, despite strong reported product growth. Social coverage is unavailable. The dated EHDN catalyst improves forward specificity, but missing analyst revisions and target-count data reduce confidence in the valuation signal.
RankAlpha Sentiment Codex - 2026-08-08
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-23catalystALN-HTT02 Phase 1 results at EHDNHigh impact
The company stated that initial results from the Phase 1 ALN-HTT02 trial in Huntington’s disease would be presented at EHDN. The EHDN Clinical Research Congress is scheduled for October 22-24, 2026; the readout remains clinically and commercially uncertain. [#SEC-8K-2026-07-30]
2026-11-06eventAMVUTTRA China commercialization pathHigh impact
Alnylam entered an exclusive agreement with BeOne Medicines for AMVUTTRA commercialization and distribution in Mainland China and Macau, subject to marketing authorization. Timing and approval probability remain unspecified. [#SEC-8K-2026-07-30]
2026-11-06catalystPost-earnings guidance reset digestionHigh impact
Q2 global net product revenue reached $1.172 billion, but management reduced full-year 2026 TTR revenue guidance from $4.4-$4.7 billion to $4.2-$4.5 billion, citing normalization of second-line ATTR-CM volume. This may keep near-term sentiment volatile despite strong underlying growth. [#SEC-8K-2026-07-30]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology